Altieri Vincenzo Maria, Castellucci Roberto, Palumbo Pietro, Verratti Vittore, Sut Michal, Olivieri Raffaella, Manco Rossella, Ricciardulli Stefano, Nicolai Michele, Criniti Pasquale, Tenaglia Raffaele Lanfranco
Department of Urology, Chair and School of Urology, University of Chieti, Chieti, Italy. vmaltieri @ alice.it
Urol Int. 2012;89(1):61-6. doi: 10.1159/000336516. Epub 2012 Jun 19.
It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables.
Between 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated.
The recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups.
From the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC.
本研究旨在评估非肌层浸润性膀胱癌（NMIBC）患者在接受经尿道膀胱癌切除术后，根据需要接受膀胱内辅助化疗或免疫治疗，1、3和5年时的复发和进展情况，并将其与欧洲癌症研究与治疗组织（EORTC）风险表进行比较。
2002年至2011年期间，共有259例NMIBC患者接受了经尿道膀胱癌切除术。根据EORTC评分系统所使用的临床和病理因素，将患者分为四组，并计算每组的复发和进展概率。
我们患者的NMIBC复发和进展率与EORTC风险评分系统中的相似。此外，在我们的样本组中，我们发现中高危组的复发率有微小但显著的降低。
从获得的结果来看，我们认为将EORTC风险表引入我们的临床实践以确定NMIBC的复发和进展至关重要。
